Skip to main content
. Author manuscript; available in PMC: 2024 Dec 13.
Published before final editing as: Dev Med Child Neurol. 2024 Dec 4:10.1111/dmcn.16199. doi: 10.1111/dmcn.16199

Table 3. Modelled assessment on primary outcome measure (interferon (IFN) score) according to treatment arm.

Comparison (vs no
treatment)		 Mean difference
(active vs no
treatment)		 98.33% CI Lower 98.33% CI Upper p-value
ABC at 3 weeks 0.23 -1.90 2.37 0.79
ABC at 6 weeks -0.25 -2.49 1.98 0.79
3TC at 3 weeks 1.73 -0.40 3.86 0.05
3TC at 6 weeks -1.37 -3.59 0.85 0.14
ABC+3TC+AZT at 3 weeks -2.45 -4.84 -0.07 0.014
ABC+3TC+AZT at 6 weeks -1.90 -4.43 0.64 0.072

ABC = abacavir; 3TC = lamivudine; AZT = zidovudine